Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.
2.

Screening for prostate cancer.

Ilic D, Neuberger MM, Djulbegovic M, Dahm P.

Cochrane Database Syst Rev. 2013 Jan 31;(1):CD004720. doi: 10.1002/14651858.CD004720.pub3. Review.

PMID:
23440794
3.

Screening for prostate cancer.

Ilic D, O'Connor D, Green S, Wilt T.

Cochrane Database Syst Rev. 2006 Jul 19;(3):CD004720. Review. Update in: Cochrane Database Syst Rev. 2013;1:CD004720.

PMID:
16856057
4.

Health-related quality of life and cost-effectiveness studies in the European randomised study of screening for prostate cancer and the US Prostate, Lung, Colon and Ovary trial.

Miller AB, Madalinska JB, Church T, Crawford D, Essink-Bot ML, Goel V, de Koning HJ, Määttänen L, Pentikäinen T.

Eur J Cancer. 2001 Nov;37(17):2154-60. Review.

PMID:
11677101
5.
6.

Statistical considerations in cancer screening programs.

Prorok PC, Connor RJ, Baker SG.

Urol Clin North Am. 1990 Nov;17(4):699-708.

PMID:
2120836
7.

The case for prostate cancer screening.

Andriole GL.

Semin Urol. 1993 May;11(2):50-3. Review.

PMID:
7689738
8.
9.
10.

Prostate cancer: estimating the benefits of PSA screening.

Vickers AJ, Lilja H.

Nat Rev Urol. 2009 Jun;6(6):301-3. doi: 10.1038/nrurol.2009.95.

11.

[Prostate cancer screening benefit very low, even after 13 years].

Blanker MH, Noordzij MA.

Ned Tijdschr Geneeskd. 2014;158:A8349. Dutch.

PMID:
25492737
12.

Cost-effectiveness of prostate specific antigen screening in the United States: extrapolating from the European study of screening for prostate cancer.

Shteynshlyuger A, Andriole GL.

J Urol. 2011 Mar;185(3):828-32. doi: 10.1016/j.juro.2010.10.079. Epub 2011 Jan 15.

PMID:
21239021
13.

Prostate cancer screening: what we know and what we need to know.

Kramer BS, Brown ML, Prorok PC, Potosky AL, Gohagan JK.

Ann Intern Med. 1993 Nov 1;119(9):914-23.

PMID:
7692780
14.

Screening for prostate cancer.

Kirkels WJ, Rietbergen JB.

Urol Res. 1997;25 Suppl 2:S53-6. Review.

PMID:
9144887
15.

No randomised trial of prostate-cancer screening in Norway.

Fosså SD, Eri LM, Skovlund E, Tveter K, Vatten L; Norwegian Urological Cancer Group.

Lancet Oncol. 2001 Dec;2(12):741-5; discussion 746-9. Review.

PMID:
11902516
16.

Update of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.

Andriole GL.

Recent Results Cancer Res. 2014;202:53-7. doi: 10.1007/978-3-642-45195-9_6.

PMID:
24531777
17.

Mortality results from the Göteborg randomised population-based prostate-cancer screening trial.

Hugosson J, Carlsson S, Aus G, Bergdahl S, Khatami A, Lodding P, Pihl CG, Stranne J, Holmberg E, Lilja H.

Lancet Oncol. 2010 Aug;11(8):725-32. doi: 10.1016/S1470-2045(10)70146-7. Epub 2010 Jul 2.

18.

Screening for prostate cancer: an updated Cochrane systematic review.

Ilic D, O'Connor D, Green S, Wilt TJ.

BJU Int. 2011 Mar;107(6):882-91. doi: 10.1111/j.1464-410X.2010.10032.x. Review.

19.

Re: Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial.

Schröder FH, Roobol MJ.

BJU Int. 2009 Jan;103(2):143-4. doi: 10.1111/j.1464-410X.2008.08257.x. Epub 2008 Dec 5. No abstract available.

20.

Epidemiology, prevention and screening for prostate cancer.

Pavone-Macaluso M.

Eur Urol. 1996;29 Suppl 2:49-53. Review.

PMID:
8717464

Supplemental Content

Support Center